Clinical Trial Detail

NCT ID NCT04146571
Title Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Recruitment Available
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

lung non-small cell carcinoma

Therapies

Ensartinib

Age Groups: adult senior

Additional content available in CKB BOOST